Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

Cancer immunotherapies, including cancer vaccines, harness and amplify the immune system’s natural ability to detect and attack cancer cells. In this illustration, immune T cells (pink) attach to a ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Hearing that your child has neuroblastoma can be frightening and overwhelming. It can be daunting to think about the treatments your child may need and how the experience will affect your child, your ...

Research at MSK Our research impact Research topics Core facilities & resources ...

With cutting-edge technology, a robust regulatory framework, and a highly skilled team, BTCF is committed to driving innovation in cell therapy research and clinical translation, helping to bring next ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo Oviedo-Mori survive — and thrive — with advanced lung cancer for 15 years.

A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and ...

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Marie-Josée Kravis Women ...